Your AI-Trained Oncology Knowledge Connection!
Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating this regimen into the frontline setting for this population.
Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.
The combination of BXCL701 and pembrolizumab produced durable responses in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to data from a phase 2a trial presented at the 2023 Genitourinary Cancers Symposium.
Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.
Laura J. Esserman, MD, MBA, discusses the effect early end points could have for clinical trials in breast cancer, how these end points could help usher in more individually tailored treatment options based on an individual patient’s disease and response, and how early end points have been used in the ongoing phase 2 I-SPY 2 trial.
Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.
As more antibody-drug conjugates emerge and investigators foresee fam-trastuzumab deruxtecan-nxki moving forward in lines of treatment for metastatic disease, the treatment landscape of hormone receptor–positive, HER2-negative breast cancer continues to expand and shift.
Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.
Closing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.
Shared insight from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the halted DELTA-1 clinical trial of ITIL-168 in melanoma, followed by a focused discussion of SITC 2022 data on emerging TIL design and manufacturing strategies.
Expert perspectives on results from C-144-01, which utilized the TIL therapy lifileucel in the setting of metastatic melanoma, and situations in which the regimen might be used in clinical practice.
A focused discussion on clinical trial data presented at SITC 2022 elucidating the biologic activity of tumor-infiltrating lymphocyte therapies.
Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.
Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.
An unshakeable belief in the power of the immune system and a deep-seated desire to make the world a better place have guided Eric J. Small, MD, throughout his career.
Dr Rugo discusses overall survival in the TROPiCS-02 trial, post-progression treatments after ribociclib and endocrine therapy in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal doses of ribociclib in hormone receptor–positive breast cancer.
Hope Rugo, MD, discusses the challenges of differentiating between HER2-low and HER2-negative metastatic breast cancer and prognostic differences in HER2+ and HER2-low metastatic breast cancer.
Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.
Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.
Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor–positive metastatic breast cancer.
First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
DNA damage homologous recombination repair genotypic variants are not created equal.
Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.
CDK4/6 inhibitors have carved out a substantial role in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer.
Andrew H. Ko, MD, discusses the multitude of treatment options for patients with gastroesophageal cancer, emerging combinations in hepatocellular carcinoma, and how HER2 expression can drive therapy decisions in colorectal cancer.
As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.
The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.
Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative breast cancer with endocrine therapy resistance, reducing the risk of disease progression by 34% vs standard chemotherapy, according to results of the phase 3 TROPiCS-02 trial.
